Sales of Novartis' heart failure drug 'Entresto' continues to grow over 20% YoY in its 7th year on the market. At this rate, the drug is expected to generate prescription sales of around KRW 70 billion by the end of this year.

The variable is the patent dispute. The company is currently awaiting its second judgment on its patent dispute with generic companies. The patent court’s ruling is expected to serve as a turning point for the early release of generics.

Entresto in its 7th year of release, continues to grow 22% YoY

According to the drug market research firm UBIST on the 5th, Entresto posted prescription sales of KRW 17.1 billion in Q2. This is a 22% YoY incr